Undue Influence and the State Board of Medical ExaminersDo anonymous patient feedback systems create a situation of undue influence?
In this issue
When to consider a Zika diagnosis August 31, 2016By Lisette HiltonAs Zika spreads and proliferates in the U.S., dermatologists need to familiarize themselves with population risk factors and techniques to diagnose and treat this disease Restoring the balance: skin microbiome in atopic dermatitis September 01, 2016By Louise GagnonResearch has demonstrated that staph aureus is in increased supply on the skin of atopic dermatitis patients coupled with less overall diversity in the number of bacteria on their skin, suggesting therapies that achieve balance in the skin microbiome could help to manage atopic dermatitis. Silver shows promise in early wound treatment September 01, 2016By Paul NicolausAn expert debunks common myths and considers future possibilities for the use of
topical nanosilver in wound healing. Common pediatric disorders in skin of color September 08, 2016By Lisette HiltonPediatric atopic dermatitis and acne have some similarities when these present in skin of color and lighter-skin children. But there are important differences when these common skin conditions affect darker skin types. An expert discusses how treatments should be approached.
Laser fundamentals September 06, 2016By Lisette HiltonA review of basic laser knowledge will help dermatologists improve operating room and patient safety as well as ensure optimal outcomes. One expert offers tips for assessing space, equipment and patients. Top 3 trends for tattoo removal September 06, 2016By Lisette HiltonThe options for tattoo removal are more numerous and more effective than ever. Picosecond technology, quad treatments, Perfluorodecalin, macrophage targeting, and Q-switched lasers allow people with ink regret more effective ways to return their skin to pre-tat status.
Clinical stage at diagnosis could affect melanoma survival September 07, 2016By Paul NicolausNYU researchers suggest a difference in the tumor progression of stage IV melanoma patients based on the initial clinical stage at original diagnosis.
Business of Dermatology
Can costs be contained? September 08, 2016By Lisette HiltonThere’s a lot of blame to go around when it comes to why drug costs are rising in dermatology. We’ll let the research do the finger pointing.